Wall Street Zen Upgrades Novavax (NASDAQ:NVAX) to “Hold”

by · The Cerbat Gem

Novavax (NASDAQ:NVAX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a research note on Tuesday, August 4th. BTIG Research reiterated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Thursday, June 11th. Finally, Zacks Research lowered shares of Novavax from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $14.00.

Check Out Our Latest Report on Novavax

Novavax Stock Performance

Shares of NVAX opened at $9.42 on Friday. Novavax has a fifty-two week low of $6.20 and a fifty-two week high of $11.97. The firm has a 50-day simple moving average of $8.62 and a 200-day simple moving average of $9.01. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -6.20 and a beta of 2.45.

Novavax (NASDAQ:NVAX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%.The firm had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $52.51 million. During the same quarter in the previous year, the firm posted $0.62 EPS. The firm’s revenue for the quarter was down 76.2% on a year-over-year basis. Equities research analysts forecast that Novavax will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVAX. AQR Capital Management LLC increased its position in shares of Novavax by 95.2% in the first quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 21,663 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Novavax by 2.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock worth $678,000 after buying an additional 2,750 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Novavax in the 1st quarter worth about $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Novavax by 16.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock worth $2,005,000 after buying an additional 44,105 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Novavax in the 1st quarter valued at about $167,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

  • Positive Sentiment: Novavax outperformed the broader market in the most recent session, according to Zacks. The article highlights the stock’s relative strength, although it does not identify a new fundamental catalyst. Novavax (NVAX) Laps the Stock Market: Here’s Why
  • Neutral Sentiment: Novavax presented at Citigroup’s Biopharma Back to School Summit, giving investors an opportunity to assess management’s strategy, pipeline and commercial outlook. No specific new deal, clinical update or financial guidance change was provided in the available summary. Novavax Presents at Citigroup’s Biopharma Back to School Summit 2026
  • Neutral Sentiment: Reported short-interest data showed zero shares and a zero-day short-interest ratio for both periods. Because the figures appear anomalous, they do not provide a reliable indication of short-covering pressure or bearish positioning.
  • Negative Sentiment: One market commentary piece included Novavax among small-cap stocks viewed skeptically, emphasizing the company’s volatility and risks associated with smaller biotechnology companies. 3 Russell 2000 Stocks We’re Skeptical Of
  • Negative Sentiment: Analysts’ average rating on Novavax remains “Hold,” suggesting limited conviction that the stock will deliver substantial near-term gains. Novavax Receives Average Rating of Hold from Analysts

About Novavax

(Get Free Report)

Novavax, Inc is a biotechnology company focused on discovering, developing and commercializing vaccines for infectious diseases. The company’s vaccine platform uses recombinant nanoparticle technology and Matrix-M, its proprietary saponin-based adjuvant, which is designed to enhance and broaden immune responses.

Novavax’s primary commercial product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in multiple markets. The vaccine has also been marketed as Covovax through partnerships in certain countries.

Featured Stories